Swiss National Bank Has $10.64 Million Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Swiss National Bank boosted its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 3.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 416,446 shares of the biotechnology company’s stock after purchasing an additional 12,100 shares during the period. Swiss National Bank owned 0.21% of Pacific Biosciences of California worth $10,640,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Advisory Services Network LLC bought a new stake in Pacific Biosciences of California in the second quarter valued at approximately $52,000. Morgan Stanley raised its stake in Pacific Biosciences of California by 10.0% in the second quarter. Morgan Stanley now owns 941,831 shares of the biotechnology company’s stock valued at $32,935,000 after buying an additional 85,278 shares during the period. Bourne Lent Asset Management Inc. raised its stake in Pacific Biosciences of California by 0.7% in the third quarter. Bourne Lent Asset Management Inc. now owns 552,850 shares of the biotechnology company’s stock valued at $14,125,000 after buying an additional 4,000 shares during the period. California Public Employees Retirement System raised its stake in Pacific Biosciences of California by 0.3% in the second quarter. California Public Employees Retirement System now owns 441,380 shares of the biotechnology company’s stock valued at $15,435,000 after buying an additional 1,292 shares during the period. Finally, Vanguard Group Inc. raised its stake in Pacific Biosciences of California by 2.4% in the second quarter. Vanguard Group Inc. now owns 18,196,904 shares of the biotechnology company’s stock valued at $636,346,000 after buying an additional 430,821 shares during the period. 85.03% of the stock is owned by hedge funds and other institutional investors.

In other Pacific Biosciences of California news, insider Peter Fromen sold 19,720 shares of the firm’s stock in a transaction on Tuesday, January 11th. The stock was sold at an average price of $14.30, for a total transaction of $281,996.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Oene Mark Van sold 41,480 shares of the firm’s stock in a transaction on Tuesday, January 11th. The stock was sold at an average price of $14.23, for a total value of $590,260.40. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by company insiders.

Shares of NASDAQ PACB opened at $12.43 on Friday. The firm has a market cap of $2.74 billion, a P/E ratio of -59.19 and a beta of 1.13. The company has a current ratio of 20.32, a quick ratio of 19.99 and a debt-to-equity ratio of 1.07. Pacific Biosciences of California, Inc. has a 1-year low of $12.04 and a 1-year high of $53.69. The business’s 50 day moving average is $21.60 and its 200-day moving average is $26.34.

Pacific Biosciences of California (NASDAQ:PACB) last announced its earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.01). The firm had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.93 million. Pacific Biosciences of California had a negative return on equity of 29.42% and a negative net margin of 30.39%. During the same quarter last year, the business posted ($0.14) EPS. Analysts forecast that Pacific Biosciences of California, Inc. will post -0.89 EPS for the current year.

Separately, assumed coverage on Pacific Biosciences of California in a research note on Monday, September 27th. They issued a “buy” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Pacific Biosciences of California currently has an average rating of “Buy” and an average price target of $46.40.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm’s products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe and Asia Pacific.

See Also: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.